Elizabeth Woodling

Elizabeth Woodling is the Senior Vice President of Quality Assurance at Navire and serves in this role at other BridgeBio affiliates, including QED Therapeutics and BridgeBio Gene Therapy. She has over 21 years of quality and regulatory experience in the biopharmaceutical and medical device industries, working in roles of increasing responsibility at BridgeBio, Mateon Therapeutics, Depomed, Elan Pharmaceuticals, and Medtronic Neurosurgery. Before joining BridgeBio, she served as Senior Director of Quality Assurance and Regulatory Affairs at Mateon Therapeutics where she developed and oversaw the quality management system, regulatory strategy, and regulatory operations to support multiple oncology clinical trials. Her expertise and leadership with inspection readiness contributed to approvals of BridgeBio’s TRUSELTIQ and Almatica Pharma’s GRALISE. She received a B.S. with honors in cellular and developmental biology from the University of California at Santa Barbara.